JP5192147B2 - ピタバスタチンカルシウムの結晶質形態 - Google Patents

ピタバスタチンカルシウムの結晶質形態 Download PDF

Info

Publication number
JP5192147B2
JP5192147B2 JP2006501997A JP2006501997A JP5192147B2 JP 5192147 B2 JP5192147 B2 JP 5192147B2 JP 2006501997 A JP2006501997 A JP 2006501997A JP 2006501997 A JP2006501997 A JP 2006501997A JP 5192147 B2 JP5192147 B2 JP 5192147B2
Authority
JP
Japan
Prior art keywords
crystalline polymorph
pitavastatin calcium
crystalline
powder diffraction
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006501997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518354A (ja
JP2006518354A5 (https=
Inventor
ファン・デル・スハーフ，パウル・アドリアーン
ブラッター，フリッツ
シェラギエヴィッツ，マルティン
シェーニング，カイ−ウーヴェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32865094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5192147(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of JP2006518354A publication Critical patent/JP2006518354A/ja
Publication of JP2006518354A5 publication Critical patent/JP2006518354A5/ja
Application granted granted Critical
Publication of JP5192147B2 publication Critical patent/JP5192147B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2006501997A 2003-02-12 2004-02-02 ピタバスタチンカルシウムの結晶質形態 Expired - Lifetime JP5192147B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03405080 2003-02-12
EP03405080.7 2003-02-12
PCT/EP2004/050066 WO2004072040A1 (en) 2003-02-12 2004-02-02 Crystalline forms of pitavastatin calcium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011127696A Division JP2011201915A (ja) 2003-02-12 2011-06-07 ピタバスタチンカルシウムの結晶質形態

Publications (3)

Publication Number Publication Date
JP2006518354A JP2006518354A (ja) 2006-08-10
JP2006518354A5 JP2006518354A5 (https=) 2007-04-05
JP5192147B2 true JP5192147B2 (ja) 2013-05-08

Family

ID=32865094

Family Applications (13)

Application Number Title Priority Date Filing Date
JP2006501997A Expired - Lifetime JP5192147B2 (ja) 2003-02-12 2004-02-02 ピタバスタチンカルシウムの結晶質形態
JP2011127696A Withdrawn JP2011201915A (ja) 2003-02-12 2011-06-07 ピタバスタチンカルシウムの結晶質形態
JP2013132593A Expired - Lifetime JP5366163B2 (ja) 2003-02-12 2013-06-25 ピタバスタチンカルシウムの新規な結晶質形態
JP2013182394A Expired - Lifetime JP5445713B2 (ja) 2003-02-12 2013-09-03 ピタバスタチンカルシウムの新規な結晶質形態
JP2013253095A Expired - Lifetime JP5500305B2 (ja) 2003-02-12 2013-12-06 ピタバスタチンカルシウムの新規な結晶質形態
JP2013264348A Withdrawn JP2014055185A (ja) 2003-02-12 2013-12-20 ピタバスタチンカルシウムの新規なアモルファス形態
JP2014155001A Expired - Fee Related JP5702494B2 (ja) 2003-02-12 2014-07-30 ピタバスタチンカルシウムの新規な結晶質形態
JP2014159459A Withdrawn JP2014205723A (ja) 2003-02-12 2014-08-05 ピタバスタチンカルシウムの新規な結晶質形態
JP2015135320A Withdrawn JP2015172086A (ja) 2003-02-12 2015-07-06 ピタバスタチンカルシウムの新規なアモルファス形態
JP2016197459A Withdrawn JP2016222737A (ja) 2003-02-12 2016-10-05 ピタバスタチンカルシウムの新規なアモルファス形態
JP2017244040A Withdrawn JP2018044009A (ja) 2003-02-12 2017-12-20 ピタバスタチンカルシウムの新規なアモルファス形態
JP2018223591A Pending JP2019031574A (ja) 2003-02-12 2018-11-29 ピタバスタチンカルシウムの新規なアモルファス形態
JP2020113164A Pending JP2020169196A (ja) 2003-02-12 2020-06-30 ピタバスタチンカルシウムの新規な結晶質形態

Family Applications After (12)

Application Number Title Priority Date Filing Date
JP2011127696A Withdrawn JP2011201915A (ja) 2003-02-12 2011-06-07 ピタバスタチンカルシウムの結晶質形態
JP2013132593A Expired - Lifetime JP5366163B2 (ja) 2003-02-12 2013-06-25 ピタバスタチンカルシウムの新規な結晶質形態
JP2013182394A Expired - Lifetime JP5445713B2 (ja) 2003-02-12 2013-09-03 ピタバスタチンカルシウムの新規な結晶質形態
JP2013253095A Expired - Lifetime JP5500305B2 (ja) 2003-02-12 2013-12-06 ピタバスタチンカルシウムの新規な結晶質形態
JP2013264348A Withdrawn JP2014055185A (ja) 2003-02-12 2013-12-20 ピタバスタチンカルシウムの新規なアモルファス形態
JP2014155001A Expired - Fee Related JP5702494B2 (ja) 2003-02-12 2014-07-30 ピタバスタチンカルシウムの新規な結晶質形態
JP2014159459A Withdrawn JP2014205723A (ja) 2003-02-12 2014-08-05 ピタバスタチンカルシウムの新規な結晶質形態
JP2015135320A Withdrawn JP2015172086A (ja) 2003-02-12 2015-07-06 ピタバスタチンカルシウムの新規なアモルファス形態
JP2016197459A Withdrawn JP2016222737A (ja) 2003-02-12 2016-10-05 ピタバスタチンカルシウムの新規なアモルファス形態
JP2017244040A Withdrawn JP2018044009A (ja) 2003-02-12 2017-12-20 ピタバスタチンカルシウムの新規なアモルファス形態
JP2018223591A Pending JP2019031574A (ja) 2003-02-12 2018-11-29 ピタバスタチンカルシウムの新規なアモルファス形態
JP2020113164A Pending JP2020169196A (ja) 2003-02-12 2020-06-30 ピタバスタチンカルシウムの新規な結晶質形態

Country Status (10)

Country Link
US (15) US20060142582A1 (https=)
EP (3) EP1592668A1 (https=)
JP (13) JP5192147B2 (https=)
CN (3) CN102285916B (https=)
AU (1) AU2004212160B2 (https=)
CA (2) CA2785954A1 (https=)
DE (1) DE202004021379U1 (https=)
PL (1) PL376557A1 (https=)
TW (4) TW201514149A (https=)
WO (1) WO2004072040A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516952A (ja) 2003-12-26 2007-06-28 日産化学工業株式会社 キノリン化合物の結晶形及びその製造法
JP2014055185A (ja) * 2003-02-12 2014-03-27 Nissan Chem Ind Ltd ピタバスタチンカルシウムの新規なアモルファス形態

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204129C1 (en) * 2003-12-26 2017-03-02 Nissan Chemical Industries, Ltd. Crystal Form of Quinoline Compound and Process for its Production
EP1711493A2 (en) * 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
WO2006079611A1 (en) * 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
US20120022102A1 (en) 2010-01-20 2012-01-26 Cadila Healthcare Limited Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof
WO2012025939A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Pitavastatin calcium and process for its preparation
EP3178812A1 (en) 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
WO2012106584A2 (en) * 2011-02-04 2012-08-09 Dr. Reddy's Laboratories Ltd. Pitavastatin salts
ITMI20111475A1 (it) * 2011-08-02 2013-02-03 Dipharma Francis Srl Forme cristalline di pitavastatina sale di calcio
EA024991B1 (ru) * 2011-09-12 2016-11-30 ФАРМА ДжРС, Д.О.О. Полиморфная форма питавастатина кальция
MX356344B (es) * 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
WO2013098773A1 (en) * 2011-12-28 2013-07-04 Dr. Reddy's Laboratories Limited Crystalline forms of pitavastatin calcium
CN104844506A (zh) * 2015-05-15 2015-08-19 苗怡文 一种治疗高血脂症的药物匹伐他汀钙化合物
CN104860882A (zh) * 2015-05-15 2015-08-26 苗怡文 一种治疗高血脂症的药物匹伐他汀钙组合物
CN105213319A (zh) * 2015-09-17 2016-01-06 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物干混悬剂
CN105125504A (zh) * 2015-09-17 2015-12-09 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物颗粒剂
US10937978B2 (en) * 2016-02-25 2021-03-02 University Of Louisville Research Foundation, Inc. Methods for forming a perovskite solar cell
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
CN109053568A (zh) * 2018-08-29 2018-12-21 南京卓康医药科技有限公司 一种高纯度匹伐他汀钙新晶型及其制备方法
CN113834795B (zh) * 2020-06-08 2024-12-03 上海医药集团股份有限公司 硫酸羟氯喹颗粒水分近红外光谱在线定量模型及其建立方法及检测方法
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2023049312A1 (en) * 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms
CN116969884A (zh) * 2023-07-28 2023-10-31 河北广祥制药有限公司 一种匹伐他汀钙单晶及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175944A (en) * 1956-06-18 1965-03-30 Upjohn Co Dihydronovobiocin and derivatives thereof
JPS61171460A (ja) 1985-01-23 1986-08-02 Dainippon Pharmaceut Co Ltd 塩酸メクロフエノキサ−ト１型結晶の製造法
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
ES2115725T3 (es) 1992-07-31 1998-07-01 Shionogi & Co Hidrocloruro de triazoliltiometiltiocefalosporina, su hidrato cristalino y la preparacion de este.
JP2575590B2 (ja) 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
GB9324931D0 (en) * 1993-12-04 1994-01-26 Pfizer Ltd Glutaramide derivatives
DE69526784T2 (de) 1994-02-25 2002-09-05 Daicel Chemical Industries, Ltd. Verfahren zur herstellung von optisch aktiven mevalonolactonen
JP3558684B2 (ja) 1994-06-28 2004-08-25 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の乾燥方法
US6335449B1 (en) * 1998-07-23 2002-01-01 Nissan Chemical Industries, Ltd. Process for the preparation of quinoline derivative and intermediate therefor
JP4749533B2 (ja) * 1999-09-30 2011-08-17 大塚化学株式会社 セファロスポリン結晶
PL361912A1 (en) * 2000-10-31 2004-10-04 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
EP1345903A1 (en) * 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
HRPK20040255B3 (en) * 2001-08-16 2006-02-28 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
AU2003226971B2 (en) * 2002-01-31 2006-11-30 Novartis Ag Process for the manufacture of HMG-CoA reductase inhibitors
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
AU2003231361A1 (en) 2002-04-17 2003-10-27 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of quinoxalinedione derivative anhydride
GB0210234D0 (en) 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds
DE202004021379U1 (de) * 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
CN100344422C (zh) * 2006-05-11 2007-10-24 朱能国 用人工用材林松木及其板材生产阻燃防潮装饰板材的方法
JP5353678B2 (ja) * 2009-12-17 2013-11-27 トヨタ自動車株式会社 車両の制御装置

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014055185A (ja) * 2003-02-12 2014-03-27 Nissan Chem Ind Ltd ピタバスタチンカルシウムの新規なアモルファス形態
JP2014198743A (ja) * 2003-02-12 2014-10-23 日産化学工業株式会社 ピタバスタチンカルシウムの新規な結晶質形態
JP2014205723A (ja) * 2003-02-12 2014-10-30 日産化学工業株式会社 ピタバスタチンカルシウムの新規な結晶質形態
JP2007516952A (ja) 2003-12-26 2007-06-28 日産化学工業株式会社 キノリン化合物の結晶形及びその製造法
JP2014205719A (ja) * 2003-12-26 2014-10-30 日産化学工業株式会社 キノリン化合物の結晶形及びその製造方法
JP2016029102A (ja) * 2003-12-26 2016-03-03 日産化学工業株式会社 キノリン化合物の結晶形及びその製造方法
JP2017061536A (ja) * 2003-12-26 2017-03-30 日産化学工業株式会社 キノリン化合物の結晶形及びその製造方法
JP2018052988A (ja) * 2003-12-26 2018-04-05 日産化学工業株式会社 キノリン化合物の結晶形及びその製造方法

Also Published As

Publication number Publication date
DE202004021379U1 (de) 2008-02-21
JP2014062115A (ja) 2014-04-10
JP2006518354A (ja) 2006-08-10
US20140364614A1 (en) 2014-12-11
PL376557A1 (pl) 2006-01-09
EP3299359A1 (en) 2018-03-28
JP2014055185A (ja) 2014-03-27
TW201514149A (zh) 2015-04-16
US20130053413A1 (en) 2013-02-28
US20160024010A1 (en) 2016-01-28
JP5500305B2 (ja) 2014-05-21
TW201345893A (zh) 2013-11-16
JP2016222737A (ja) 2016-12-28
JP2014205723A (ja) 2014-10-30
CN1747934A (zh) 2006-03-15
TW201213311A (en) 2012-04-01
JP2014024848A (ja) 2014-02-06
WO2004072040A1 (en) 2004-08-26
EP2500339A1 (en) 2012-09-19
US20060142582A1 (en) 2006-06-29
CA2785954A1 (en) 2004-08-26
JP5445713B2 (ja) 2014-03-19
AU2004212160B2 (en) 2009-05-14
US20200148644A1 (en) 2020-05-14
CN101219992A (zh) 2008-07-16
JP2015172086A (ja) 2015-10-01
US20120101126A1 (en) 2012-04-26
TWI485135B (zh) 2015-05-21
JP2013177466A (ja) 2013-09-09
US8853405B2 (en) 2014-10-07
US20210002227A1 (en) 2021-01-07
US20230322680A1 (en) 2023-10-12
US8557993B2 (en) 2013-10-15
US20140005402A1 (en) 2014-01-02
US20090182008A1 (en) 2009-07-16
TW200420541A (en) 2004-10-16
CN102285916B (zh) 2015-02-25
CA2513837A1 (en) 2004-08-26
JP5702494B2 (ja) 2015-04-15
AU2004212160A1 (en) 2004-08-26
JP2014198743A (ja) 2014-10-23
US20180029987A1 (en) 2018-02-01
JP5366163B2 (ja) 2013-12-11
JP2011201915A (ja) 2011-10-13
JP2019031574A (ja) 2019-02-28
CN100374422C (zh) 2008-03-12
JP2020169196A (ja) 2020-10-15
JP2018044009A (ja) 2018-03-22
US20220169614A1 (en) 2022-06-02
US20190256469A1 (en) 2019-08-22
US20170022163A1 (en) 2017-01-26
US20180346425A1 (en) 2018-12-06
CN102285916A (zh) 2011-12-21
CN101219992B (zh) 2011-08-31
EP1592668A1 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
JP5366163B2 (ja) ピタバスタチンカルシウムの新規な結晶質形態
HK1164873A (en) Crystalline forms of pitavastatin calcium

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080414

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080414

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110607

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110615

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130131

R150 Certificate of patent or registration of utility model

Ref document number: 5192147

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160208

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

EXPY Cancellation because of completion of term